Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tracks bleeding prevention in kids with hemophilia a

NCT ID NCT07088458

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 29 times

Summary

This study follows 40 children aged 7 to 12 with hemophilia A who are already prescribed damoctocog alfa pegol, a medicine that replaces missing clotting factor. Researchers will collect information from routine care—like bleeding episodes and health diaries—over two years to see how well the treatment prevents bleeds in everyday life. No extra visits or tests are required.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.